Grifols, S.A. is engaged in the acquisition, manufacture, preparation and sale of therapeutic products, mainly plasma derivatives. The company operates through the bioscientific, hospital, diagnostic, biosupplies and other divisions.
Grifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA margin 15.9%.
Grifols stock has been heavely punished during 2021.
First the pandemic difficulted the plasma collection. We must take into account the stimulus checks and the unemployment benefits from the US goverment wich might have disuaded people from going to the plasma collection centers to get some extra income. I'll be looking forward for the data on the plasma...
A nice triangle at the end of a long way down. Even though we did not face the ultimate action, the chances are the stage is set for upside. The best case is to see the short-lived break down but the solo break up is valid as well.
After surpassing Fib 0.5, it looks like the stock is heading towards 0.382 level (21.81). Right now the company is immersed in a share repurchase program since 12/03/2021 and it has already acquired 19.23% of its €125 million valued shares objective. Maybe the company's financial advisers are playing with chart patterns in order to confirm its trend and go beyond...
68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (specially Q4 ones), I expect a jump from 21.61 to 26 in a matter of 2...
Focused on hemoderivatives (blood plasma), Grifols is great value by most of investors. Even though the company might be one day spitted by any scandal on how it is gathering the plasma in the US, americans have got a high stake on it and today it is focusing on an hyperimmune immunoglobulin with specific antibodies against the SARS-CoV-2 virus. Grifols estimated...
I think in this covid19 scenario grifols is a really good pic with the medical improvements that they are offering.
It's a safe pick so i recommend reading about this coorporation and make your own research.
Griffols is evolving in an ascending canal with 3 support level. The stock has drawn this week a very long hammer (10% length !) on the second support. Griffols has a very good behavior with long shadow hammer with only 1,6% of long shadow hammer not initiating bullish trends. We can predict a rebound in the coming weeks, with target the resistance of the canal...
GRFS: Grifols
2018-08-16 08:00:00
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
